SUO Annual Meeting

“My talk [highlights] unmet research needs that need to be addressed to further improve the adjuvant treatment landscape for our patients,” said Pavlos Msaouel, MD, PhD.

A study examining a broader range of domains among patients receiving cystectomy found a large signal of differences in health-related quality of life.

“No question, we see that there’s a lot of heterogeneity in how penile cancer is managed across the United States,” says Philippe E. Spiess, MD, MS, FACS.

A majority of women were able to return to sexual activity post-surgery without compromising oncological outcomes.

"Some of the discussion going on right now is how to improve the morbidity of bladder cancer treatment by pursuing such things…as bladder sparing approaches when feasible…and so, I think that’s very exciting,” says Mohummad M. Siddiqui, MD.

Recurrence is commonly associated with low-grade upper tract urothelial carcinoma and may be predicted by smoking status and tumor size.

“The idea was really to bring together a multidisciplinary group of experts and to discuss…highly relevant, translational research that’s going on, and to…address some of the really critical clinical questions as well,” says Seth P. Lerner, MD, FACS.

According to extended follow-up from the phase 3 Checkmate 274 trial, nivolumab continued to demonstrate improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.

The primary objective of the study was to assess the benefit of cytoreductive nephrectomy relative to immunotherapy regimens utilizing checkpoint inhibitors.

Phase 1 data suggest the anti–PD-1 immune checkpoint inhibitor is safe and tolerable in the neoadjuvant setting for patients with nonmetastatic high-risk clear cell renal cell carcinoma.

No new safety signals were reported with the androgen receptor pathway inhibitor.

Patients undergoing pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.

Over half of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

The in-depth interview covers the data that led to the NMIBC approval, outlines the appropriate patient population for pembrolizumab, and reviews side-effect management with the immune checkpoint inhibitor.

Researchers examined the prevalence of germline mutations, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

Clinical activity with MK-6482 was observed in both RCC and non-RCC lesions.

The algorithm was applied to 50 patients who underwent radical prostatectomy between 2008 and 2018.

Ten-year data showed high overall survival and recurrence-free survival rates with Mohs surgery in patients with localized penile cancer.

The app also provides patients with a socially distant alternative to in-person visits during the COVID-19 pandemic.

Cancer-specific survival is noninferior for active surveillance compared with primary intervention in select patients with small renal masses suspicious for renal cell carcinoma.

Blue light cystoscopy identified patients with bladder cancer recurrence post-BCG that would have been missed with standard white light cystoscopy alone.

A separate analysis presented at SUO assessed the impact of nadofaragene firadenovec on the incidence and time to cystectomy.

Arjun V. Balar, MD, walks through the patient discussion when weighing the use of pembrolizumab (Keytruda).

Of 13 studies evaluated by investigators for the meta-analysis, only 1 was a randomized controlled trial.

Physicians involved in clinical trials should have the patient in mind “from the very conception of the design to the conduct of the study to dissemination of the results,” says Angela B. Smith, MD, MS.

The researchers also determined that healthcare disparities were associated with cystectomy delay.

The vast majority of patients reported being "pleased" with their medical encounter.

The majority of patients surveyed reported having at least some interest in sexual activity following surgery.

Combining the 4Kscore or ExoDx with multiparametric MRI appears to be the optimal strategy for detecting high-grade prostate cancer, a study from the University of California, San Francisco suggests. However, it is reasonable to consider biomarker testing only in patients who want to avoid biopsy, said first author Claire M. de la Calle, MD.

Clinicians are taught that renal cell carcinoma is radioresistant, but modalities such as stereotactic body radiation therapy (SBRT) can be safe and efficacious in certain patients with RCC. In this interview, Vitaly Margulis, MD, outlines the advantages of SBRT and offers a preview of the RADVAX trial, which combines radiotherapy and immunotherapy.